U.S. markets open in 6 hours 47 minutes
  • S&P Futures

    3,885.50
    -13.25 (-0.34%)
     
  • Dow Futures

    31,432.00
    -77.00 (-0.24%)
     
  • Nasdaq Futures

    13,234.50
    -45.25 (-0.34%)
     
  • Russell 2000 Futures

    2,260.60
    -14.20 (-0.62%)
     
  • Crude Oil

    60.10
    -0.54 (-0.89%)
     
  • Gold

    1,717.20
    -5.80 (-0.34%)
     
  • Silver

    26.23
    -0.45 (-1.70%)
     
  • EUR/USD

    1.2011
    -0.0049 (-0.41%)
     
  • 10-Yr Bond

    1.4460
    0.0000 (0.00%)
     
  • Vix

    23.35
    -4.60 (-16.46%)
     
  • GBP/USD

    1.3872
    -0.0049 (-0.35%)
     
  • USD/JPY

    106.8400
    +0.1100 (+0.10%)
     
  • BTC-USD

    48,831.54
    +2,751.21 (+5.97%)
     
  • CMC Crypto 200

    979.32
    -7.33 (-0.74%)
     
  • FTSE 100

    6,588.53
    +105.10 (+1.62%)
     
  • Nikkei 225

    29,408.17
    -255.33 (-0.86%)
     

Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter 2020 Financial Results on July 30, 2020

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its second quarter 2020 financial results on Thursday, July 30, 2020 after the close of financial markets. Following the announcement, Company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows:

Thursday, July 30, 2020
1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time

  • Telephone 866-248-8441 (domestic) or +1 720-452-9102 (international); conference ID 1128188

  • Webcast with slides available at www.seattlegenetics.com in the Investors section. A webcast replay will be archived on the Company’s website.

About Seattle Genetics

Seattle Genetics, Inc. is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in people’s lives. ADCETRIS® (brentuximab vedotin) and PADCEVTM (enfortumab vedotin-ejfv) use the Company’s industry-leading antibody-drug conjugate (ADC) technology. ADCETRIS is approved in certain CD30-expressing lymphomas, and PADCEV is approved in certain metastatic urothelial cancers. TUKYSATM (tucatinib), a small molecule tyrosine kinase inhibitor, is approved in certain HER2-positive metastatic breast cancers. The Company is headquartered in the Seattle, Washington area, with locations in California, Switzerland and the European Union. For more information on our robust pipeline, visit www.seattlegenetics.com and follow @SeattleGenetics on Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200709005173/en/

Contacts

Investors
Peggy Pinkston
(425) 527-4160
ppinkston@seagen.com

Media
Monique Greer
(425) 527-4641
mgreer@seagen.com